The North America acute respiratory distress syndrome (ARDS) treatment market is expected to reach USD 4,096,703.49 thousand by 2030, from USD 1,807,544.80 thousand in 2022, growing at the CAGR of 11.2% in the forecast period of 2023 to 2030. Market Segmentation North America Acute Respiratory Distress Syndrome (Ards) Treatment Market, By Type (Mechanical Ventilation, Corticosteroids, Antiviral Medication, Extracorporeal Membrane Oxygenation (ECMO), Tocilizumab, and Others), Cause ( Sepsis, Inhalation of Harmful Substances, Severe Pneumonia, and Others), Route of Administration (Parenteral, Oral, and Others), End User (Hospitals, Specialty Clinics, Home Healthcare, and Others), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), Country ( U.S., Canada, and Mexico) - Industry Trends and Forecast to 2030 Overview of North America Acute Respiratory Distress Syndrome (ARDS) Treatment Market Dynamics Driver • Increasing prevalence and incidence of acute lung injury in the market Restraint • High cost of device and treatment Opportunity • Strategic initiatives joined with new product launches by market players Market Players Some of the major market players operating in the North America Acute Respiratory Distress Syndrome (ARDS) treatment market are listed below: • Gilead Sciences, Inc. • Terumo Medical Corporation • Getinge . • LivaNova PLC • Medtronic • ResMed • Fisher & Paykel Healthcare Limited. • Drägerwerk AG & Co. KGaA • NIPRO • Fresenius SE & Co. KGaA • Hamilton Medical • Pfizer Inc. • WEINMANN Emergency Medical Technology GmbH + Co. KG • EUROSETS • Armstrong Medical • nice Neotech Medical Systems Pvt. Ltd. • Besmed Health Business Corp.

1 INTRODUCTION 16 1.1 OBJECTIVES OF THE STUDY 16 1.2 MARKET DEFINITION 16 1.3 OVERVIEW OF NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET 16 1.4 LIMITATIONS 18 1.5 MARKETS COVERED 18 2 MARKET SEGMENTATION 20 2.1 MARKETS COVERED 20 2.2 GEOGRAPHICAL SCOPE 21 2.3 YEARS CONSIDERED FOR THE STUDY 22 2.4 CURRENCY AND PRICING 22 2.5 DBMR TRIPOD DATA VALIDATION MODEL 23 2.6 MULTIVARIATE MODELLING 26 2.7 TYPE LIFELINE CURVE 26 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 27 2.9 DBMR MARKET POSITION GRID 28 2.10 MARKET END USER COVERAGE GRID 29 2.11 VENDOR SHARE ANALYSIS 30 2.12 SECONDARY SOURCES 31 2.13 ASSUMPTIONS 31 3 EXECUTIVE SUMMARY 32 4 PREMIUM INSIGHTS 35 4.1 PESTEL ANALYSIS 36 4.2 PORTER’S FIVE FORCES 37 4.3 INSURANCE REIMBURSEMENT 38 4.3.1 CENTER FOR MEDICARE SERVICES (CMS)-ELSO (EXTRACORPOREAL LIFE SUPPORT ORGANIZATION) 38 4.3.2 HEALTH RESOURCES AND SERVICES ADMINISTRATION 38 4.3.3 ABBOTT CODING GUIDE FOR ECMO 39 4.3.4 CENTRAL GOVERNMENT HEALTH SCHEME (CGHS) 39 4.3.5 CERN HEALTH INSURANCE SCHEME 40 4.3.6 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) - (MEDICARE & MEDICAID) 40 4.3.7 AMERICAN HOSPITAL ASSOCIATION 41 4.4 PIPELINE ANALYSIS 42 4.5 PRICING ANALYSIS 44 5 MARKET OVERVIEW 45 5.1 DRIVERS 47 5.1.1 INCREASING PREVALENCE AND INCIDENCE OF ACUTE LUNG INJURY 47 5.1.2 WIDE RANGE OF RISK FACTORS FOR ARDS TREATMENT 47 5.1.3 RISING RATE OF AIR POLLUTION AND UNHEALTHY LIFESTYLE 48 5.1.4 INCREASING ACCIDENT RATES AND TRAUMA CAUSING ARDS 48 5.2 RESTRAINTS 49 5.2.1 COMPLICATIONS ASSOCIATED WITH THE TREATMENT 49 5.2.2 HIGH COST OF DEVICES AND TREATMENT 49 5.3 OPPORTUNITIES 50 5.3.1 RISING HEALTHCARE EXPENDITURE TO IMPROVE TREATMENT FACILITIES 50 5.3.2 STRATEGIC INITIATIVES JOINED WITH NEW PRODUCT LAUNCH BY MARKET PLAYERS 50 5.3.3 IMPROVING AWARENESS REGARDING ARD SYNDROME 51 5.4 CHALLENGES 52 5.4.1 STRINGENT RULES & REGULATIONS 52 5.4.2 MULTIPLE CHALLENGES FACED BY ICU STAFF 53 6 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE 54 6.1 OVERVIEW 55 6.2 MECHANICAL VENTILATION 58 6.2.1 HIGH-FLOW NASAL O2 59 6.2.2 BI-LEVEL POSITIVE AIRWAY PRESSURE 59 6.2.3 CONTINUOUS POSITIVE AIRWAY PRESSURE 59 6.2.4 PRONE POSITION VENTILATION 59 6.2.5 OTHERS 60 6.3 CORTICOSTEROIDS 60 6.3.1 METHYLPREDNISOLONE 61 6.3.2 DEXAMETHASONE 61 6.3.3 OTHERS 61 6.4 ANTIVIRAL MEDICATION 62 6.4.1 RIBAVIRIN 63 6.4.2 OSELTAMIVIR 63 6.4.3 OTHERS 63 6.5 EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO) 63 6.6 TOCILIZUMAB 64 6.7 OTHERS 64 7 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE 65 7.1 OVERVIEW 66 7.2 SEPSIS 69 7.3 INHALATION OF HARMFUL SUBSTANCES 69 7.4 SEVERE PNEUMONIA 70 7.5 OTHERS 70 8 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 71 8.1 OVERVIEW 72 8.2 PARENTERAL 75 8.2.1 INTRAVENOUS 75 8.2.2 INTRAMUSCULAR 75 8.3 ORAL 76 8.4 OTHERS 76 9 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER 77 9.1 OVERVIEW 78 9.2 HOSPITALS 81 9.3 SPECIALTY CLINICS 81 9.4 HOME HEALTHCARE 82 9.5 OTHERS 82 10 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 83 10.1 OVERVIEW 84 10.2 DIRECT TENDER 87 10.3 HOSPITAL PHARMACY 87 10.4 RETAIL PHARMACY 88 10.5 ONLINE PHARMACY 88 11 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION 89 11.1 NORTH AMERICA 91 11.1.1 U.S 96 11.1.2 CANADA 101 11.1.3 MEXICO 106 12 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, COMPANY LANDSCAPE 111 12.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 111 13 SWOT ANALYSIS 112 14 NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT, CPS 113 14.1 GILEAD SCIENCES INC 113 14.1.1 COMPANY SNAPSHOT 113 14.1.2 REVENUE ANALYSIS 114 14.1.3 COMPANY SHARE ANALYSIS 114 14.1.4 PRODUCT PORTFOLIO 115 14.1.5 RECENT DEVELOPMENT 115 14.2 TERUMO CORPORATION 116 14.2.1 COMPANY SNAPSHOT 116 14.2.2 REVENUE ANALYSIS 116 14.2.3 COMPANY SHARE ANALYSIS 117 14.2.4 PRODUCT PORTFOLIO 117 14.2.5 RECENT DEVELOPMENT 117 14.3 GETINGE 118 14.3.1 COMPANY SNAPSHOT 118 14.3.2 REVENUE ANALYSIS 118 14.3.3 COMPANY SHARE ANALYSIS 119 14.3.4 PRODUCT PORTFOLIO 119 14.3.5 RECENT DEVELOPMENT 119 14.4 LIVANOVA PLC 120 14.4.1 COMPANY SNAPSHOT 120 14.4.2 REVENUE ANALYSIS 120 14.4.3 COMPANY SHARE ANALYSIS 121 14.4.4 PRODUCT PORTFOLIO 121 14.4.5 RECENT DEVELOPMENTS 121 14.5 MEDTRONIC 122 14.5.1 COMPANY SNAPSHOT 122 14.5.2 REVENUE ANALYSIS 122 14.5.3 COMPANY SHARE ANALYSIS 123 14.5.4 PRODUCT PORTFOLIO 123 14.5.5 RECENT DEVELOPMENTS 123 14.6 ARMSTRONG MEDICAL 124 14.6.1 COMPANY SNAPSHOT 124 14.6.2 PRODUCT PORTFOLIO 124 14.6.3 RECENT DEVELOPMENT 124 14.7 BESMED HEALTH BUSINESS CORP 125 14.7.1 COMPANY SNAPSHOT 125 14.7.2 PRODUCT PORTFOLIO 125 14.7.3 RECENT DEVELOPMENTS 126 14.8 DRÄGERWERK AG & CO. KGAA 127 14.8.1 COMPANY SNAPSHOT 127 14.8.2 REVENUE ANALYSIS 127 14.8.3 PRODUCT PORTFOLIO 128 14.8.4 RECENT DEVELOPMENTS 128 14.9 EUROSETS 129 14.9.1 COMPANY SNAPSHOT 129 14.9.2 PRODUCT PORTFOLIO 129 14.9.3 RECENT DEVELOPMENT 129 14.10 FISHER & PAYKEL HEALTHCARE LIMITED 130 14.10.1 COMPANY SNAPSHOT 130 14.10.2 REVENUE ANALYSIS 130 14.10.3 PRODUCT PORTFOLIO 131 14.10.4 RECENT DEVELOPMENTS 131 14.11 FRESENIUS SE & CO. KGAA 132 14.11.1 COMPANY SNAPSHOT 132 14.11.2 REVENUE ANALYSIS 132 14.11.3 PRODUCT PORTFOLIO 133 14.11.4 RECENT DEVELOPMENT 133 14.12 HAMILTON MEDICAL 134 14.12.1 COMPANY SNAPSHOT 134 14.12.2 PRODUCT PORTFOLIO 134 14.12.3 RECENT DEVELOPMENT 134 14.13 NICE NEOTECH MEDICAL SYSTEMS PVT.LTD 135 14.13.1 COMPANY SNAPSHOT 135 14.13.2 PRODUCT PORTFOLIO 135 14.13.3 RECENT DEVELOPMENT 135 14.14 NIPRO 136 14.14.1 COMPANY SNAPSHOT 136 14.14.2 REVENUE ANALYSIS 136 14.14.3 PRODUCT PORTFOLIO 137 14.14.4 RECENT DEVELOPMENT 137 14.15 PFIZER INC 138 14.15.1 COMPANY SNAPSHOT 138 14.15.2 REVENUE ANALYSIS 138 14.15.3 PRODUCT PORTFOLIO 139 14.15.4 RECENT DEVELOPMENT 139 14.16 RESMED 140 14.16.1 COMPANY SNAPSHOT 140 14.16.2 REVENUE ANALYSIS 140 14.16.3 PRODUCT PORTFOLIO 141 14.16.4 RECENT DEVELOPMENT 141 14.17 WEINMANN EMERGENCY MEDICAL TECHNOLOGY GMBH + CO. KG 142 14.17.1 COMPANY SNAPSHOT 142 14.17.2 PRODUCT PORTFOLIO 142 14.17.3 RECENT DEVELOPMENT 142 15 QUESTIONNAIRE 143 16 RELATED REPORTS 146